Denise P. Carter Buys 31,813 Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) COO Denise P. Carter acquired 31,813 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was acquired at an average price of $0.78 per share, with a total value of $24,814.14. Following the transaction, the chief operating officer now directly owns 47,092 shares of the company’s stock, valued at approximately $36,731.76. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Quoin Pharmaceuticals Stock Performance

Shares of NASDAQ QNRX opened at $0.80 on Friday. The company’s fifty day moving average is $0.59 and its two-hundred day moving average is $0.88. The firm has a market capitalization of $3.17 million, a P/E ratio of -0.11 and a beta of 1.96. Quoin Pharmaceuticals, Ltd. has a one year low of $0.48 and a one year high of $6.32.

Quoin Pharmaceuticals (NASDAQ:QNRX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.36. During the same quarter in the previous year, the company posted ($2.13) EPS. On average, sell-side analysts forecast that Quoin Pharmaceuticals, Ltd. will post -3.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A hedge fund recently bought a new stake in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.